Procter & Gamble Health Q1 FY27 Results: PAT Jumps 45%, Revenue Rises 7%

Procter & Gamble Health began FY27 on a positive note, reporting steady growth in both revenue and profit for the quarter ended June 30, 2026. The company said its performance was driven by strong demand for its brands, improved retail execution, supply chain efficiencies and continued product innovation.

Procter & Gamble Health Q1 FY27 Financial Highlights

For the quarter ended June 30, 2026, Procter & Gamble Health reported:

*Operational PAT excludes the one-time gain from the sale of an immovable asset.

The company said the sharp rise in reported profit was supported by higher sales, stronger supply chain and go-to-market capabilities, along with one-time proceeds from the sale of an immovable property.

What Drove the Growth?

According to the company, revenue growth was supported by:

• Strong performance of its core brands
• Better retail execution across markets
• Positive consumer response to new product innovations
• Improved supply chain and distribution capabilities 

These factors helped the company maintain healthy growth during the quarter.

Also check: Pharmaceuticals Stocks

Management Commentary

Milind Thatte, Managing Director of Procter & Gamble Health India, said the company has started FY27 with strong growth momentum carried forward from the previous financial year.

He added that the company's strategy focuses on delivering high-quality, science-backed products, strengthening brand communication, improving retail execution and enhancing operational productivity. The company also remains focused on creating long-term value for consumers and shareholders through innovation and efficient business operations.

Read More: Best Gold ETFs in August 2026 Based on 5-Year CAGR: LIC MF Gold ETF, UTI Gold ETF and More!

About Procter & Gamble Health

Procter & Gamble Health is one of India's leading companies in the vitamins, minerals and supplements (VMS) segment. Its portfolio includes well-known healthcare brands such as Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion.The company is part of Procter & Gamble, which markets a broad range of consumer brands across multiple categories in around 70 countries.

Procter & Gamble Health Share Price Movement

Procter & Gamble Health share price (NSE: PGHL) was trading at ₹6,114.00, down 5.42% (₹350.50) in the afternoon session on August 6. The stock opened at ₹6,460.00, touched an intraday high of ₹6,670.00, and slipped to a low of ₹6,070.00.

Conclusion

Procter & Gamble Health delivered a solid start to FY27 with steady revenue growth and a sharp increase in reported profit. While part of the profit growth was supported by a one-time gain, the company's operational performance also improved, reflecting strong brand demand, better execution and continued investment in innovation.

Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Readers should conduct their own research and form an independent opinion before making any financial decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Turn insights into action - Open Free Demat Account with Angel One and start investing instantly.